Immunology, Dendritic cell, Immune system, Immunotherapy and Cancer are her primary areas of study. The study incorporates disciplines such as Melanoma and Cell biology in addition to Immunology. Her Dendritic cell research incorporates themes from Myeloid, Cancer research, Progenitor cell, CD14 and Vaccination.
Her research integrates issues of Stage, Cervical intraepithelial neoplasia and Lymphoma in her study of Immune system. Her Immunotherapy research is multidisciplinary, incorporating elements of Cytotoxic T cell, Regulation of gene expression and Transporter. Her work on Cervical cancer and Cancer immunotherapy as part of general Cancer study is frequently linked to Context, therefore connecting diverse disciplines of science.
Her primary areas of study are Immunology, Cancer research, Dendritic cell, Immune system and T cell. As a member of one scientific family, she mostly works in the field of Immunology, focusing on Cytotoxic T cell and, on occasion, Molecular biology. Her work carried out in the field of Cancer research brings together such families of science as Cervical cancer, Cell, Ex vivo and CD40.
Tanja D. de Gruijl has researched Dendritic cell in several fields, including Cellular differentiation, Myeloid, Myeloid leukemia, Melanoma and Cell biology. Her Immune system study combines topics in areas such as Bone marrow and Vaccination. Tanja D. de Gruijl has included themes like Priming, Cytokine and FOXP3 in her T cell study.
Tanja D. de Gruijl spends much of her time researching Cancer research, Immune system, Immunotherapy, T cell and Tumor microenvironment. Many of her research projects under Cancer research are closely connected to CpG site with CpG site, tying the diverse disciplines of science together. Her Immune system study is concerned with the field of Immunology as a whole.
Her Immunotherapy research includes themes of Ex vivo, Oncology and Oncolytic virus. Her T cell study combines topics from a wide range of disciplines, such as Dendritic cell, CD8, Lymph node, Degranulation and Chronic lymphocytic leukemia. Her Dendritic cell research is multidisciplinary, incorporating perspectives in CTLA-4 and Cell biology.
Her scientific interests lie mostly in Cancer research, Antigen, Immunotherapy, Internal medicine and Oncology. Her work deals with themes such as Cervical cancer, Immune modulation, Immune system and Vaccination, which intersect with Cancer research. Tanja D. de Gruijl has included themes like Breast cancer, Primary tumor, Melanoma and Lymph in her Immune system study.
Her Antigen study integrates concerns from other disciplines, such as T cell, Antigen-presenting cell and Cell biology. Cell biology is closely attributed to CD8 in her study. Her Immunotherapy study incorporates themes from Tumor microenvironment, Ovarian cancer, Radiation therapy and Respiratory virus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Functional delivery of viral miRNAs via exosomes
D. Michiel Pegtel;Katherine Cosmopoulos;David A. Thorley-Lawson;Monique A. J. van Eijndhoven.
Proceedings of the National Academy of Sciences of the United States of America (2010)
Langerin is a natural barrier to HIV-1 transmission by Langerhans cells.
Lot de Witte;Alexey Nabatov;Marjorie Pion;Donna Fluitsma.
Nature Medicine (2007)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J.M. Van den Eertwegh;Jurjen Versluis;H. Pieter Van den Berg;Saskia J.A.M. Santegoets.
Lancet Oncology (2012)
Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation
Claudia C. Sombroek;Anita G. M. Stam;Allan J. Masterson;Sinéad M. Lougheed.
Journal of Immunology (2002)
Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD40-Targeted Adenoviral Vector
Bryan W. Tillman;Tanja D. De Gruijl;Sylvia A. Luykx-de Bakker;Rik J. Scheper.
Journal of Immunology (1999)
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rodney A. Rosalia;Luis J. Cruz;Suzanne van Duikeren;Angelino T. Tromp.
Biomaterials (2015)
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
Tanja D. de Gruijl;Alfons J. M. van den Eertwegh;Herbert M. Pinedo;Rik J. Scheper.
Cancer Immunology, Immunotherapy (2008)
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors
Allan J Masterson;Claudia C Sombroek;Tanja D De Gruijl;Yvo M F Graus.
Blood (2002)
Defining the critical hurdles in cancer immunotherapy
Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal.
Journal of Translational Medicine (2011)
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia.
Johan W. Molling;Tanja D. de Gruijl;Judith Glim;Maria Moreno.
International Journal of Cancer (2007)
VU University Medical Center
Vrije Universiteit Amsterdam
Vrije Universiteit Amsterdam
Vrije Universiteit Amsterdam
VU University Medical Center
Washington University in St. Louis
University of Amsterdam
University of Helsinki
Vrije Universiteit Amsterdam
VU University Medical Center
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: